视网膜中央静脉阻塞的危险因素研究(4)
[7]Li M，Hu X，Huang J，et al.Impact of retinal vein occlusion on stroke incidence：a Meta-analysis[J].J Am Heart Assoc，2016，5(12)：e004703.
[8]Woo SC，Lip GY，Lip PL.Associations of retinal artery occlusion and retinal vein occlusion to mortality，stroke，and myocardial infarction：a systematic review[J].Eye (Lond)，2016，30(8)：1031-1038.
[9]Napal JJ，Neila S，Pérez-Montes R，et al.The role of coagulation disorders in patients with retinal vein occlusion[J].QJM，2016，109(2)：97-102.
[10]Chapin J，Carlson K，Christos PJ，et al.Risk factors and treatment strategies in patients with retinal vascular occlusions[J].Clin Appl Thromb Hemost，2015，21(7)：672-677.
[11]The Eye Disease Case-Control Study Group.Risk factors for central retinal vein occlusion[J].Arch Ophthalmol，1996，114(5)：545-554.
[12]Hayreh SS，Zimmerman B，McCarthy MJ，et al.Systemic diseases associated with various types of retinal vein occlusion[J].American journal of ophthalmology，2001，131(1)：61-77.
[13]Sivalingam A，Brown GC，Magargal LE.The ocular ischemic syndrome Ⅱ.Mortality and systemic morbidity [J].Int ophthalmol，1989，13：187-191.
[14]Russo PD，Damante G，Pasca S，et al.Thrombophilic mutations as risk factor for retinal vein occlusion：a case-control study[J].Clin Appl Thromb Hemost，2015，21(4)：373-377.
[15]Folsom AR，Alonso A，George KM，et al.Prospective study of plasma D-dimer and incident venous thromboembolism：the atherosclerosis risk in communities (ARIC) study[J].Thromb Res，2015，136(4)：781-785.
[16]Soomro AY，Guerchicoff A，Nichols DJ，et al.The current role and future prospects of D-dimer biomarker[J].Eur Heart J Cardiovasc Pharmacother，2016，2(3)：175-184.
[17]Sathe PM，Patwa UD.D-Dimer in acute care[J].Int J Crit Illn Inj Sci，2014，4(3)：229-232.
(收稿日期：2017-05-18 本文編辑：祁海文), http://www.100md.com(樊利敏 杨波 计青 李乃洋)
[8]Woo SC，Lip GY，Lip PL.Associations of retinal artery occlusion and retinal vein occlusion to mortality，stroke，and myocardial infarction：a systematic review[J].Eye (Lond)，2016，30(8)：1031-1038.
[9]Napal JJ，Neila S，Pérez-Montes R，et al.The role of coagulation disorders in patients with retinal vein occlusion[J].QJM，2016，109(2)：97-102.
[10]Chapin J，Carlson K，Christos PJ，et al.Risk factors and treatment strategies in patients with retinal vascular occlusions[J].Clin Appl Thromb Hemost，2015，21(7)：672-677.
[11]The Eye Disease Case-Control Study Group.Risk factors for central retinal vein occlusion[J].Arch Ophthalmol，1996，114(5)：545-554.
[12]Hayreh SS，Zimmerman B，McCarthy MJ，et al.Systemic diseases associated with various types of retinal vein occlusion[J].American journal of ophthalmology，2001，131(1)：61-77.
[13]Sivalingam A，Brown GC，Magargal LE.The ocular ischemic syndrome Ⅱ.Mortality and systemic morbidity [J].Int ophthalmol，1989，13：187-191.
[14]Russo PD，Damante G，Pasca S，et al.Thrombophilic mutations as risk factor for retinal vein occlusion：a case-control study[J].Clin Appl Thromb Hemost，2015，21(4)：373-377.
[15]Folsom AR，Alonso A，George KM，et al.Prospective study of plasma D-dimer and incident venous thromboembolism：the atherosclerosis risk in communities (ARIC) study[J].Thromb Res，2015，136(4)：781-785.
[16]Soomro AY，Guerchicoff A，Nichols DJ，et al.The current role and future prospects of D-dimer biomarker[J].Eur Heart J Cardiovasc Pharmacother，2016，2(3)：175-184.
[17]Sathe PM，Patwa UD.D-Dimer in acute care[J].Int J Crit Illn Inj Sci，2014，4(3)：229-232.
(收稿日期：2017-05-18 本文編辑：祁海文), http://www.100md.com(樊利敏 杨波 计青 李乃洋)